Related references
Note: Only part of the references are listed.Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A New Initiative on Precision Medicine
Francis S. Collins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial
Richard B. Moss et al.
LANCET RESPIRATORY MEDICINE (2015)
Targeted Correction and Restored Function of the CFTR Gene in Cystic Fibrosis Induced Pluripotent Stem Cells
Ana M. Crane et al.
STEM CELL REPORTS (2015)
Ivacaftor: From Bench to Bedside ... and Back Again
Kevin Molloy et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
Steven M. Rowe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Gene therapy in cystic fibrosis
David K. Armstrong et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2014)
Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease
Peter J. Barry et al.
CHEST (2014)
A new era in the treatment of cystic fibrosis
Matthew A. Lane et al.
CLINICAL MEDICINE (2014)
Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
Penny Whiting et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
Fredrick Van Goor et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
Kris De Boeck et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
ATALUREN TREATMENT OF PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY
Katharine Bushby et al.
MUSCLE & NERVE (2014)
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Guido Veit et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Deborah M. Cholon et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding
Deborah Cohen et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
Elton Kerem et al.
LANCET RESPIRATORY MEDICINE (2014)
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
Michael P. Boyle et al.
LANCET RESPIRATORY MEDICINE (2014)
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)
Edward F. McKone et al.
LANCET RESPIRATORY MEDICINE (2014)
Synergy-Based Small-Molecule Screen Using a Human Lung Epithelial Cell Line Yields ΔF508-CFTR Correctors That Augment VX-809 Maximal Efficacy
Puay-Wah Phuan et al.
MOLECULAR PHARMACOLOGY (2014)
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Jane C. Davies et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Cystic Fibrosis Pulmonary Guidelines Chronic Medications for Maintenance of Lung Health
Peter J. Mogayzel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients
Gerald Schwank et al.
CELL STEM CELL (2013)
Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi
Carlos M. Farinha et al.
FEBS JOURNAL (2013)
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
Hong Yu Ren et al.
MOLECULAR BIOLOGY OF THE CELL (2013)
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Tsukasa Okiyoneda et al.
NATURE CHEMICAL BIOLOGY (2013)
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Johanna F. Dekkers et al.
NATURE MEDICINE (2013)
Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications
Malena Cohen-Cymberknoh et al.
THORAX (2013)
A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays
Stuart P. McElroy et al.
PLOS BIOLOGY (2013)
Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial
Jane Davies et al.
LANCET RESPIRATORY MEDICINE (2013)
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation
Isabelle Sermet-Gaudelus
EUROPEAN RESPIRATORY REVIEW (2013)
Stratified medicine: drugs meet genetics
Ian P. Hall
EUROPEAN RESPIRATORY REVIEW (2013)
Development of primary human nasal epithelial cell cultures for the study of cystic fibrosis pathophysiology
F. de Courcey et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Emerging Targeted Therapies in Cancer
Lucian R. Chirieac
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Patrick A. Flume et al.
CHEST (2012)
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Haihui Yu et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Drug bests cystic-fibrosis mutation
Heidi Ledford
NATURE (2012)
Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung
Alejandro A. Pezzulo et al.
NATURE (2012)
Cystic Fibrosis: therapies targeting specific gene defects
Rebecca M. Thursfield et al.
PAEDIATRIC RESPIRATORY REVIEWS (2012)
A Periciliary Brush Promotes the Lung Health by Separating the Mucus Layer from Airway Epithelia
Brian Button et al.
SCIENCE (2012)
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
J. P. Clancy et al.
THORAX (2012)
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis
Zhi-wei Cai et al.
ACTA PHARMACOLOGICA SINICA (2011)
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
M. Wilschanski et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Assessment of CFTR function in homozygous R117H-7T subjects
R. A. de Nooijer et al.
JOURNAL OF CYSTIC FIBROSIS (2011)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Is CFTR-delF508 Really Absent from the Apical Membrane of the Airway Epithelium?
Lee A. Borthwick et al.
PLOS ONE (2011)
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Elizabeth O. Lillie et al.
PERSONALIZED MEDICINE (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study
Helen L. Barr et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
Isabelle Sermet-Gaudelus et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Ceramide Is Increased in the Lower Airway Epithelium of People with Advanced Cystic Fibrosis Lung Disease
Malcolm Brodlie et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Primary bronchial epithelial cell culture from explanted cystic fibrosis lungs
Malcolm Brodlie et al.
EXPERIMENTAL LUNG RESEARCH (2010)
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening
C. Thauvin-Robinet et al.
JOURNAL OF MEDICAL GENETICS (2009)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
Eitan Kerem et al.
LANCET (2008)
Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis
Volker Teichgraeber et al.
NATURE MEDICINE (2008)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects
Silvia G. Bompadre et al.
JOURNAL OF GENERAL PHYSIOLOGY (2007)
Cystic fibrosis mortality and survival in the UK: 1947-2003
J. A. Dodge et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Barriers to treatment adherence for children with cystic fibrosis and asthma: What gets in the way?
Avani C. Modi et al.
JOURNAL OF PEDIATRIC PSYCHOLOGY (2006)
Cystic fibrosis: terminology and diagnostic algorithms
K. De Boeck et al.
THORAX (2006)
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis
MR Elkins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study
EF McKone et al.
LANCET (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
TGF-β1 genotype and accelerated decline in lung function of patients with cystic fibrosis
PD Arkwright et al.
THORAX (2000)
Share Paper
